Symbols

RVNC(Delisted)

Revance Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RVNC

Revance Therapeutics, Inc.

A commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings

Industry

Established Date

08/10/1999

Listing Date

02/06/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

597

Fiscal Year Ends

12-31

Website

www.revance.com

Security Type

Common stock

Office address

1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203

Business

Introduction

Revance Therapeutics, Inc., a Delaware corporation, was founded on August 10, 1999 as Essentia Biosystems, Inc. The company is a professional clinical-stage biopharmaceutical company focused on the development, manufacture and commercialization of abnormal-type botulinum toxin products for beauty and treatment. Botulinum toxin is a good protein that is widely used in cosmetic and therapeutic indications and is a multi-billion dollar market in the United States and other countries. Currently approved and commercially available botulinum toxin is an injection type. RT001, the company's main product candidate, is a topical formulation of botulinum toxin type a, which is considered to have significant advantages over existing injectable botulinum toxin market products. The Company's second product candidate, RT002, is a new formulation of the botulinum toxin type for injection, which is designed to be more targeted and longer-lasting compared to other botulinum toxin injection products. These product candidates combine the company's purified botulinum toxin and proprietary peptide delivery systems. The company has worldwide distribution rights for its two product candidates.

Company Financials

EPS

RVNC has released its 2024 Q3 earnings. EPS was reported at -0.37, versus the expected -0.38, beating expectations. The chart below visualizes how RVNC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RVNC has released its 2024 Q3 earnings report, with revenue of 59.88M, reflecting a YoY change of 10.66%, and net profit of -38.12M, showing a YoY change of 73.00%. The Sankey diagram below clearly presents RVNC's revenue sources and cost distribution.